Page 29 - Orvosoktatás - Aki a szívizom incfartust túlélte

29

Irodalom:

1. Mancia G, et al. 2013 ESH/ESC Guidelines for the 12. Vlachopoulos C, et al. Prediction of cardiovascular
management of arterial hypertension: the Task events and all-cause mortality with central
Force for the management of arterial hypertension haemodynamics: a systematic review and meta-
of the European Society of Hypertension (ESH) analysis. Eur Heart J. 2010;31:1865–71.
and of the European Society of Cardiology (ESC). 13. Jamerson K, et al. Benazepril plus amlodipine or
Eur Heart J. 2013;34:2159–219. hydrochlorothiazide for hypertension in high-risk
2. Endo A. A historical perspective on the discovery patients. N Engl J Med. 2008;359:2417–28.
of statins. Proc Jpn Acad Ser B Phys Biol Sci. 14. Law MR, et al. Quantifying effect of statins on low
2010;86:484–93. density lipoprotein cholesterol, ischaemic heart
3. Nantel P, de Cotret PR. The evolution of angiotensin disease, and stroke: systematic review and meta-
blockade in the management of cardiovascular analysis. BMJ. 2003;326:1423.
disease. Can J Cardiol. 2010;26(Suppl 1):7E–13E. 15. Athyros VG, et al. Treatment with atorvastatin to
4. Fox KM. Efficacy of perindopril in reduction of the National Cholesterol Educational Program
cardiovascular events among patients with stable goal versus ‘usual’ care in secondary coronary
coronary artery disease: randomised, double- heart disease prevention. The GREek Atorvastatin
blind, placebo-controlled, multicentre trial (the and Coronary-heart-disease Evaluation (GREACE)
EUROPA study). Lancet. 2003;362:782–8. study. Curr Med Res Opin. 2002;18:220–8.
5. Montalescot G, et al. 2013 ESC guidelines on the 16. Athyros VG, et al. Effect of statins and ACE
management of stable coronary artery disease: inhibitors alone and in combination on clinical
the Task Force on the management of stable outcome in patients with coronary heart disease.
coronary artery disease of the European Society J Hum Hypertens. 2004;18:781–8.
of Cardiology. Eur Heart J. 2013;34:2949–3003 17. Sever P, et al. Potential synergy between lipid-
6. Makani H, et al. Effect of renin-angiotensin system lowering and blood-pressure-lowering in the
blockade on calcium channel blocker-associated Anglo-Scandinavian Cardiac Outcomes Trial. Eur
peripheral edema. Am J Med. 2011;124:128–35. Heart J. 2006;27:2982–8.
7. Jackson R, et al. Treatment with drugs to lower 18. Sever PS. The Anglo-Scandinavian cardiac
blood pressure and blood cholesterol based outcomes trial: implications and further
on an individual’s absolute cardiovascular risk. outcomes. Hypertension. 2012;60:248–59.
Lancet. 2005;365:434–41. 19. Mason RP. Mechanisms of plaque stabilization
8. Borghi C, et al. Combination therapy in the for the dihydropyridine calcium channel
extended cardiovascular continuum: a focus on blocker amlodipine: review of the evidence.
perindopril and amlodipine. J Cardiovasc Med Atherosclerosis. 2002;165:191–9.
(Hagerstown). 2015;16(5):390–9. 20. Ferrari R. Optimizing the treatment of hypertension
9. Mason RP, Marche P, Hintze TH. Novel vascular and stable coronary artery disease: clinical
biology of third-generation L-type calcium evidence for fixed-combination perindopril/
channel antagonists: ancillary actions of amlodipine. Curr Med Res Opin. 2008;24:3543–57.
amlodipine. Arterioscler Thromb Vasc Biol. 21. Watson S, et al. Prevention of coronary and
2003;23:2155–63. stroke events with perindopril, amlodipine and
10. Nissen SE et al. Effect of antihypertensive atorvastatin in combination: sub-group analysis
agents on cardiovascular events in patients with of the Anglo-Scandinavian Cardiac Outcomes
coronary disease and normal blood pressure: the Trial (ASCOT). J Hypertens. 2014;32:e63 (abstract).
CAMELOT study: a randomized controlled trial. 22. Chowdhury R, et al. Adherence to cardiovascular
JAMA 2004;10(292):2217-25 therapy: a meta-analysis of prevalence and clinical
11. Williams B, et al. Differential impact of blood consequences. Eur Heart J. 2013;34:2940–8.
pressure-lowering drugs on central aortic 23. Chapman RH, et al. Predictors of adherence with
pressure and clinical outcomes: principal results antihypertensive and lipid-lowering therapy. Arch
of the Conduit Artery Function Evaluation (CAFE) Intern Med. 2005;165:1147–52.
study. Circulation. 2006;113:1213–25.